Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 22:48 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Golimumab for the Treatment of Refractory Behcet's Uveitis
NCT04218565 · Wenjie Zheng · PHASE2 · terminated · last registry update 2023-04-07 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “only one patient enrolled” | – | Registry record, Wenjie Zheng |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TNF within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-03-26Results posted on the registry: ECOG-ACRIN Cancer Research Group, Infliximab + Intravenous Immunoglobulin Therapy (NCT04438382)
- 2024-02-23Phase 3 first posted: CMC Ambroise Paré, CT-P13 (NCT06274294)
- 2023-12-12Results posted on the registry: Janssen Research & Development, LLC, Guselkumab Dose 1 + Guselkumab Dose 2 (NCT03662542)
- 2023-11-13Results posted on the registry: UCB Biopharma SRL, Certolizumab pegol (NCT04740814)
- 2023-10-27Also stopped (terminated): Emory University, Infliximab + Placebo (NCT03004443)
- 2023-10-23Results posted on the registry: Celltrion, CT-P13 SC (Infliximab) (NCT03945019)
- 2023-09-29Phase 3 first posted: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), Infliximab subcutaneous + Immunosuppressive Agents (NCT06059989)
- 2023-09-28Results posted on the registry: Celltrion, CT-P13 SC (Infliximab) (NCT04205643)
- 2023-07-27Results posted on the registry: UCB Biopharma SRL, Bimekizumab + Certolizumab pegol (NCT03215277)
- 2023-07-17Phase 3 first posted: Odense University Hospital, Infliximab + Methylprednisolone (NCT05947669)
- 2023-07-05Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Certolizumab (CIMZIA® ; TNF-α antagonist) + Placebo (NaCl 0.9 % solution) (NCT05930613)
- 2023-06-07Results posted on the registry: Emory University, Infliximab + Placebo (NCT03004443)
- 2023-05-03Phase 3 first posted: Alvotech Swiss AG, AVT05 (proposed biosimilar to golimumab) + Simponi (Golimumab) (NCT05842213)
- 2023-04-21Results posted on the registry: Daniel Benjamin, Infliximab + Abatacept (NCT04593940)
- 2023-02-08Results posted on the registry: Novartis Pharmaceuticals, Ruxolitinib (RUX) + Best Available Therapy (BAT) (NCT02913261)
- 2023-01-25Results posted on the registry: Nichi-Iko Pharmaceutical Co., Ltd., NI-071 + Remicade (NCT02990806)
- 2023-01-20Results posted on the registry: Johnson & Johnson Private Limited, Golimumab (NCT03733925)
- 2023-01-19Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, STOP arm (NCT05689879)
- 2023-01-03Phase 3 first posted: University of Pennsylvania, Guselkumab + Golimumab (NCT05669833)
- 2022-12-21Phase 3 first posted: Children's Hospital Medical Center, Cincinnati, Infliximab (NCT05660746)
- 2022-09-19Also stopped (terminated): Mario Negri Institute for Pharmacological Research, Tocilizumab + Etanercept (NCT03100253)
- 2022-08-16Results posted on the registry: National Institute of Allergy and Infectious Diseases (NIAID), Infliximab + Methylprednisolone (NCT02495077)
- 2022-08-09Also stopped (withdrawn): Children's Hospital of Fudan University, Infliximab (NCT04530877)
- 2022-07-20Also stopped (withdrawn): Hospices Civils de Lyon, Infliximab + Cyclophosphamide (NCT03088293)
- 2022-07-14Results posted on the registry: Janssen Research & Development, LLC, Golimumab + Placebo (NCT02846545)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision